Scagliotti GV, et al. Nintedanib + pemetrexed/cisplatin in patients with unresectable MPM: phase III results from the LUME-Meso trial. IASLC 2018, abstract PL02.09.
Verhoogd risico op kanker bij kinderen met IBD
jun 2020 | IBD, Maag-darm-leveroncologie